CHD1
Basic information
Region (hg38): 5:98853985-98929007
Links
Phenotypes
GenCC
Source:
- Pilarowski-Bjornsson syndrome (Limited), mode of inheritance: AD
- Pilarowski-Bjornsson syndrome (Supportive), mode of inheritance: AD
- Pilarowski-Bjornsson syndrome (Limited), mode of inheritance: Unknown
Clinical Genomic Database
Source:
Condition | Inheritance | Intervention Categories | Intervention/Rationale | Manifestation Categories | References |
---|---|---|---|---|---|
Pilarowski-Bjornsson syndrome | AD | General | Genetic knowledge may be beneficial related to issues such as selection of optimal supportive care, informed medical decision-making, prognostic considerations, and avoidance of unnecessary testing | Craniofacial; Neurologic | 28866611 |
ClinVar
This is a list of variants' phenotypes submitted to
Variants pathogenicity by type
Statistics on ClinVar variants can assist in determining whether a specific variant type in the CHD1 gene is commonly pathogenic or not.
In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.
Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.
Variant type | Pathogenic | Likely pathogenic | VUS | Likely benign | Benign | Sum |
---|---|---|---|---|---|---|
synonymous | 24 | 24 | ||||
missense | 144 | 13 | 164 | |||
nonsense | 8 | |||||
start loss | 0 | |||||
frameshift | 5 | |||||
inframe indel | 2 | |||||
splice donor/acceptor (+/-2bp) | 0 | |||||
splice region | 6 | 1 | 7 | |||
non coding | 4 | |||||
Total | 0 | 5 | 156 | 38 | 8 |
Variants in CHD1
This is a list of pathogenic ClinVar variants found in the CHD1 region.
You can filter this list by clicking the number of variants in the Variants pathogenicity by type table.
Position | Type | Phenotype | Significance | ClinVar |
---|---|---|---|---|
5-98856390-C-T | Pilarowski-Bjornsson syndrome | Uncertain significance (Jul 26, 2022) | ||
5-98856391-G-A | not specified | Uncertain significance (Sep 21, 2023) | ||
5-98856408-T-C | not specified | Uncertain significance (Mar 24, 2023) | ||
5-98856411-G-A | Uncertain significance (Mar 01, 2023) | |||
5-98856460-AAGG-A | Benign (Sep 01, 2020) | |||
5-98856462-G-A | not specified | Uncertain significance (Feb 07, 2023) | ||
5-98856471-T-C | not specified | Uncertain significance (Jul 09, 2021) | ||
5-98856487-T-C | not specified | Uncertain significance (Aug 12, 2022) | ||
5-98856537-C-G | Pilarowski-Bjornsson syndrome | Uncertain significance (Aug 25, 2023) | ||
5-98856555-T-C | not specified | Uncertain significance (Dec 22, 2023) | ||
5-98856555-T-G | Likely benign (Jun 01, 2023) | |||
5-98856556-T-C | See cases | Uncertain significance (Oct 30, 2020) | ||
5-98856564-G-A | CHD1-related disorder | Benign (Jan 01, 2024) | ||
5-98856582-C-T | not specified | Uncertain significance (May 03, 2023) | ||
5-98856600-C-T | not specified | Uncertain significance (Apr 25, 2022) | ||
5-98856619-G-C | Pilarowski-Bjornsson syndrome | Uncertain significance (Dec 12, 2018) | ||
5-98856627-G-C | Pilarowski-Bjornsson syndrome | Uncertain significance (Aug 17, 2020) | ||
5-98856633-G-A | Uncertain significance (Mar 08, 2022) | |||
5-98856658-A-G | CHD1-related disorder | Benign (Dec 31, 2019) | ||
5-98856659-A-G | CHD1-related disorder | Likely benign (Jul 01, 2022) | ||
5-98856663-G-A | not specified | Uncertain significance (Jul 23, 2024) | ||
5-98856663-G-C | Pilarowski-Bjornsson syndrome | Uncertain significance (Sep 19, 2020) | ||
5-98856721-A-G | Pilarowski-Bjornsson syndrome | Uncertain significance (Oct 26, 2020) | ||
5-98858207-T-C | Pilarowski-Bjornsson syndrome | Uncertain significance (Aug 03, 2023) | ||
5-98858214-G-A | Pilarowski-Bjornsson syndrome | Uncertain significance (Dec 24, 2019) |
GnomAD
Source:
Gene | Type | Bio Type | Transcript | Coding Exons | Length |
---|---|---|---|---|---|
CHD1 | protein_coding | protein_coding | ENST00000284049 | 35 | 71333 |
pLI Probability LOF Intolerant | pRec Probability LOF Recessive | Individuals with no LOFs | Individuals with Homozygous LOFs | Individuals with Heterozygous LOFs | Defined | p |
---|---|---|---|---|---|---|
1.00 | 8.98e-10 | 125728 | 0 | 17 | 125745 | 0.0000676 |
Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible in Transcript | |
---|---|---|---|---|---|---|
Missense | 4.21 | 507 | 853 | 0.594 | 0.0000430 | 11327 |
Missense in Polyphen | 48 | 255.07 | 0.18818 | 3227 | ||
Synonymous | 0.531 | 277 | 288 | 0.960 | 0.0000142 | 2976 |
Loss of Function | 8.28 | 9 | 96.9 | 0.0928 | 0.00000512 | 1289 |
LoF frequencies by population
Ethnicity | Sum of pLOFs | p |
---|---|---|
African & African-American | 0.00 | 0.00 |
Ashkenazi Jewish | 0.00 | 0.00 |
East Asian | 0.0000544 | 0.0000544 |
Finnish | 0.0000470 | 0.0000462 |
European (Non-Finnish) | 0.000107 | 0.000105 |
Middle Eastern | 0.0000544 | 0.0000544 |
South Asian | 0.0000980 | 0.0000980 |
Other | 0.00 | 0.00 |
dbNSFP
Source:
- Function
- FUNCTION: ATP-dependent chromatin-remodeling factor which functions as substrate recognition component of the transcription regulatory histone acetylation (HAT) complex SAGA. Regulates polymerase II transcription. Also required for efficient transcription by RNA polymerase I, and more specifically the polymerase I transcription termination step. Regulates negatively DNA replication. Not only involved in transcription-related chromatin-remodeling, but also required to maintain a specific chromatin configuration across the genome. Is also associated with histone deacetylase (HDAC) activity (By similarity). Required for the bridging of SNF2, the FACT complex, the PAF complex as well as the U2 snRNP complex to H3K4me3. Functions to modulate the efficiency of pre-mRNA splicing in part through physical bridging of spliceosomal components to H3K4me3 (PubMed:18042460, PubMed:28866611). Required for maintaining open chromatin and pluripotency in embryonic stem cells (By similarity). {ECO:0000250|UniProtKB:P40201, ECO:0000269|PubMed:18042460, ECO:0000269|PubMed:28866611}.;
- Disease
- DISEASE: Pilarowski-Bjornsson syndrome (PILBOS) [MIM:617682]: An autosomal dominant disorder characterized by developmental delay, speech apraxia, intellectual disability, autism, and facial dysmorphic features. Some patients may have seizures. {ECO:0000269|PubMed:28866611}. Note=The disease is caused by mutations affecting the gene represented in this entry.;
- Pathway
- miR-targeted genes in epithelium - TarBase;miR-targeted genes in lymphocytes - TarBase;miR-targeted genes in muscle cell - TarBase
(Consensus)
Recessive Scores
- pRec
- 0.173
Intolerance Scores
- loftool
- 0.0234
- rvis_EVS
- -0.81
- rvis_percentile_EVS
- 12.05
Haploinsufficiency Scores
- pHI
- 0.883
- hipred
- Y
- hipred_score
- 0.853
- ghis
- 0.571
Essentials
- essential_gene_CRISPR
- E
- essential_gene_CRISPR2
- E
- essential_gene_gene_trap
- N
- gene_indispensability_pred
- E
- gene_indispensability_score
- 0.592
Gene Damage Prediction
All | Recessive | Dominant | |
---|---|---|---|
Mendelian | Medium | Medium | Medium |
Primary Immunodeficiency | Medium | Medium | Medium |
Cancer | Medium | Medium | Medium |
Mouse Genome Informatics
- Gene name
- Chd1
- Phenotype
- vision/eye phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); skeleton phenotype; behavior/neurological phenotype (the observable actions or reactions of mammalian organisms that are manifested through development and lifespan); embryo phenotype; growth/size/body region phenotype; normal phenotype; mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); craniofacial phenotype; cellular phenotype;
Gene ontology
- Biological process
- chromatin remodeling;regulation of transcription by RNA polymerase II;covalent chromatin modification;DNA duplex unwinding;positive regulation by host of viral transcription
- Cellular component
- fibrillar center;nucleus;nucleoplasm;cytoplasm
- Molecular function
- DNA binding;ATP-dependent DNA helicase activity;protein binding;ATP binding;methylated histone binding